amlodipine has been researched along with Diabetic Angiopathies in 28 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension." | 9.15 | Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011) |
| " The primary aim of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) was to compare the effects of fosinopril and amlodipine on serum lipids and diabetes control in NIDDM patients with hypertension." | 9.08 | Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. ( Byington, RP; Di Mauro, P; Guarisco, R; Pahor, M; Strollo, F; Strollo, G; Tatti, P, 1998) |
| "In AMANDHA trial, the addition of manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions." | 5.24 | Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine. ( Martinez-Martin, FJ; Roca-Cusachs, A; Saiz-Satjes, M, 2017) |
| "To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy." | 5.16 | Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| "A total of 170 outpatients aged 50-75 years with mild to moderate hypertension (SBP >130 and <180 mmHg and DBP >80 and <100 mmHg) and type 2 diabetes were randomly treated with aliskiren 300 mg or amlodipine 10 mg, both given once daily for 24 weeks, according to a prospective, open label, blinded-end point, parallel group design." | 5.16 | Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Monti, C; Mugellini, A; Zoppi, A, 2012) |
| "The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension." | 5.15 | Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011) |
| "To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden." | 5.13 | Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action." | 5.11 | Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. ( Ando, D; Hirawa, N; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| " The primary aim of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) was to compare the effects of fosinopril and amlodipine on serum lipids and diabetes control in NIDDM patients with hypertension." | 5.08 | Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. ( Byington, RP; Di Mauro, P; Guarisco, R; Pahor, M; Strollo, F; Strollo, G; Tatti, P, 1998) |
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| "The coexistence of type 2 diabetes mellitus and hypertension increases the risk of cardiovascular diseases." | 2.72 | Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J). ( Daida, H; Hayashi, D; Ikeda, S; Imai, Y; Kawamori, R; Kishimoto, J; Kitagawa, A; Miyauchi, K; Tanaka, Y; Yamazaki, T, 2006) |
| "The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause." | 2.71 | Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003) |
| "All participants had baseline diabetic nephropathy, overt proteinuria, and hypertension and were recruited between 1996 and 1999." | 2.71 | Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2005) |
| "Amlodipine treatment also increased cardiac SDF-1/CXCR4 expression and gave rise to activation of VEGF/Akt/eNOS signaling in bone marrow." | 1.43 | Amlodipine Ameliorates Ischemia-Induced Neovascularization in Diabetic Rats through Endothelial Progenitor Cell Mobilization. ( Dong, L; Ferro, A; Kang, L; Sun, J; Xie, J; Xu, B, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 17 (60.71) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, T | 1 |
| Wang, J | 1 |
| Yu, Y | 1 |
| Yu, J | 1 |
| Kang, MK | 1 |
| Chung, WB | 1 |
| Hong, SK | 1 |
| Kim, OR | 1 |
| Ihm, SH | 1 |
| Chang, K | 1 |
| Seung, KB | 1 |
| Sun, J | 1 |
| Xie, J | 1 |
| Kang, L | 1 |
| Ferro, A | 1 |
| Dong, L | 1 |
| Xu, B | 1 |
| Saiz-Satjes, M | 1 |
| Martinez-Martin, FJ | 1 |
| Roca-Cusachs, A | 1 |
| Baguet, JP | 1 |
| Asmar, R | 1 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 1 |
| Mallion, JM | 1 |
| Nilsson, PM | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 2 |
| Remuzzi, G | 1 |
| Packham, D | 1 |
| Lewis, JB | 2 |
| Parving, HH | 1 |
| Lambers Heerspink, HJ | 1 |
| Ram, CV | 1 |
| Sachson, R | 1 |
| Littlejohn, T | 1 |
| Qian, C | 1 |
| Shojaee, A | 1 |
| Stoakes, KA | 1 |
| Neutel, JM | 1 |
| Fogari, R | 2 |
| Mugellini, A | 2 |
| Destro, M | 1 |
| Corradi, L | 1 |
| Lazzari, P | 2 |
| Zoppi, A | 2 |
| Preti, P | 1 |
| Derosa, G | 2 |
| Maffioli, P | 1 |
| Monti, C | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Tokudome, G | 1 |
| Horiguchi, M | 1 |
| Hayashi, H | 1 |
| Kobayashi, H | 1 |
| Ishikawa, M | 1 |
| Hosoya, T | 1 |
| Messerli, FH | 1 |
| Hunsicker, LG | 3 |
| Pfeffer, MA | 1 |
| Porush, JG | 1 |
| Rouleau, JL | 1 |
| Drury, PL | 1 |
| Esmatjes, E | 1 |
| Hricik, D | 1 |
| Parikh, CR | 1 |
| Raz, I | 1 |
| Vanhille, P | 1 |
| Wiegmann, TB | 1 |
| Wolfe, BM | 1 |
| Locatelli, F | 1 |
| Goldhaber, SZ | 1 |
| Lewis, EJ | 2 |
| Winer, N | 1 |
| Folker, A | 1 |
| Murphy, JA | 1 |
| Hung, E | 1 |
| Bard, M | 1 |
| Perkelvald, A | 1 |
| Sowers, JR | 1 |
| Bakris, GL | 1 |
| Yasuda, G | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Umemura, S | 1 |
| Tochikubo, O | 1 |
| Friedman, AN | 1 |
| Selhub, J | 1 |
| Bostom, AG | 1 |
| Iwashima, Y | 1 |
| Okada, M | 1 |
| Haneda, M | 1 |
| Yoshida, T | 1 |
| Kawamori, R | 1 |
| Daida, H | 1 |
| Tanaka, Y | 1 |
| Miyauchi, K | 1 |
| Kitagawa, A | 1 |
| Hayashi, D | 1 |
| Kishimoto, J | 1 |
| Ikeda, S | 1 |
| Imai, Y | 1 |
| Yamazaki, T | 1 |
| Uzu, T | 1 |
| Sawaguchi, M | 1 |
| Maegawa, H | 1 |
| Kashiwagi, A | 1 |
| Lindgren, P | 1 |
| Buxton, M | 1 |
| Kahan, T | 1 |
| Poulter, NR | 2 |
| Dahlöf, B | 2 |
| Sever, PS | 2 |
| Wedel, H | 2 |
| Jönsson, B | 1 |
| Gupta, AK | 1 |
| Dobson, J | 1 |
| Karalliedde, J | 1 |
| Smith, A | 1 |
| DeAngelis, L | 1 |
| Mirenda, V | 1 |
| Kandra, A | 1 |
| Botha, J | 1 |
| Ferber, P | 1 |
| Viberti, G | 1 |
| Tatti, P | 1 |
| Pahor, M | 1 |
| Byington, RP | 1 |
| Di Mauro, P | 1 |
| Guarisco, R | 1 |
| Strollo, G | 1 |
| Strollo, F | 1 |
| Califf, RM | 1 |
| Granger, CB | 1 |
| Zamorski, MA | 1 |
| Staessen, JA | 1 |
| Birkenhäger, WH | 1 |
| Fagard, RH | 1 |
| Rodby, RA | 1 |
| Studney, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [NCT00021918] | 0 participants | Observational | 2001-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for amlodipine and Diabetic Angiopathies
| Article | Year |
|---|---|
Hypertension and diabetes: should we treat early surrogates? What are the cons?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseas | 2009 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
Evolution of calcium antagonists: past, present, and future.
Topics: Amlodipine; Calcium Channel Blockers; Diabetic Angiopathies; Edema; Humans; Hypertension; Hypertroph | 2003 |
Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients.
Topics: Amlodipine; Calcium Channel Blockers; Diabetic Angiopathies; Dihydropyridines; Enalapril; Fosinopril | 2000 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
20 trials available for amlodipine and Diabetic Angiopathies
| Article | Year |
|---|---|
Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine.
Topics: Adult; Aged; Albumins; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2017 |
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, | 2011 |
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2012 |
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabet | 2012 |
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
Topics: Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 2005 |
Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2005 |
Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Cardiovascular Syst | 2005 |
Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J).
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2006 |
Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART).
Topics: Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabeti | 2007 |
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus | 2008 |
Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Diabetic Angiopathies | 2008 |
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; An | 2008 |
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood | 1998 |
Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
CCBs vs ACE inhibitors in patients with diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
A clinical trial in type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium Channel Block | 2001 |
3 other studies available for amlodipine and Diabetic Angiopathies
| Article | Year |
|---|---|
Comparison of real-world effectiveness between valsartan and non-RAS inhibitor monotherapy on the incidence of new diabetes in Chinese hypertensive patients: An electronic health recording system based study.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blo | 2019 |
Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats.
Topics: Amlodipine; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Experimental; Dia | 2016 |
Amlodipine Ameliorates Ischemia-Induced Neovascularization in Diabetic Rats through Endothelial Progenitor Cell Mobilization.
Topics: Amlodipine; Animals; Cell Movement; Cytokines; Diabetic Angiopathies; Dose-Response Relationship, Dr | 2016 |